N-(tert.-Butyl)-2-ethylbutanamid | 66875-74-9

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: N-(tert.-Butyl)-2-ethylbutanamid
• 英文别名: N-tert-butyl-2-ethylbutanamide
• CAS: 66875-74-9
• 化学式: C₁₀H₂₁NO
• mdl: MFCD00996288
• 分子量: 171.283
• InChiKey: RTWNZMOLNIXRHK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  12
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  2-(tert-butylamino)-3-ethylpent-2-enenitrile 生成 N-(tert.-Butyl)-2-ethylbutanamid
  参考文献：
  名称：

  KIMPE N. DE; VERHE R.; BUYCK L. DE; CHYS J.; SCHAMP N., J. ORG. CHEM., 1978, 43, NO 13, 2670-2672

  摘要：

  DOI：

文献信息

• PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER
  申请人：BARTBERGER Michael David

  公开号：US20110319378A1

  公开（公告）日：2011-12-29

  The present invention provides MDM2 inhibitor compounds of Formula I, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.

  本发明提供了公式I的MDM2抑制剂化合物，其中变量如上所定义，这些化合物可用作治疗剂，特别是用于治疗癌症。本发明还涉及含有MDM2抑制剂的药物组合物。
• NOVEL ANTIBODY-DRUG CONJUGATES AND THE USE OF SAME IN THERAPY
  申请人：UNIVERSITE FRANCOIS RABELAIS

  公开号：US20160151515A1

  公开（公告）日：2016-06-02

  Disclosed are novel antibody-drug conjugates and use thereof in therapy, in particular in anticancer or anti-inflammatory therapy, as well as synthetic products useful as linkers, composed of a linker head and a linker body, and also a method for preparing the linkers and the antibody-drug conjugates.

  本发明涉及新型抗体药物偶联物及其在治疗中的应用，特别是在抗癌或抗炎症治疗中的应用，以及作为连接剂的合成产物，由连接剂头和连接剂体组成，并且还提供了制备连接剂和抗体药物偶联物的方法。
• TRIOXANE DIMERS HAVING HIGH ANTICANCER AND LONG-LASTING ANTIMALARIAL ACTIVITIES
  申请人：Posner Gary H.

  公开号：US20090291923A1

  公开（公告）日：2009-11-26

  The invention provides novel trioxane dimers having formulae III, IV or V: methods for their preparation, pharmaceutical compositions containing these compounds, and methods for treating cancer and/or malaria using these compounds and compositions.
• Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer
  申请人：Amgen Inc.

  公开号：US20210179560A1

  公开（公告）日：2021-06-17

  The present invention provides MDM2 inhibitor compounds of Formula I, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.